Furthermore, since BET bromodomain inhibitors have also been shown to reduce the frequency of CFU-Cs in Asxl1Y588XTg BM cells (19), the combinatory effect of KDM6B inhibitor with other targeted therapeutics (e.g., BET inhibitor) could potentially deepen treatment responses and further improve the survival of patients with ASXL1-mutated myeloid malignancies. The gene discussed is ASXL1; the disease is myeloid neoplasm.